Publications

1. Wang Y, Jia M, Liang C, Sheng N, Wang X, Wang F, Luo Y, Jiang J, Cai L, Niu H, Zhu D, Nesa EU, Young CY, Yuan H. Anterior gradient 2 increases long-chain fatty acid uptake via stabilizing FABP1 and facilitates lipid accumulation. Int J Biol Sci. 2021; 17 (3):834-847 Epub 2021 Feb 08
   View PubMed
2. Wang D, Xu Q, Yuan Q, Jia M, Niu H, Liu X, Zhang J, Young CY, Yuan H. Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab. Oncogene. 2019 May; 38 (18):3458-3474 Epub 2019 Jan 15
   View PubMed
3. Jia M, Guo Y, Zhu D, Zhang N, Li L, Jiang J, Dong Y, Xu Q, Zhang X, Wang M, Yu H, Wang F, Tian K, Zhang J, Young CYF, Lou H, Yuan H. Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-kappaB pathway. Biochim Biophys Acta Mol Basis Dis. 2018 May; 1864 (5 Pt A):1622-1633 Epub 2018 Feb 01
   View PubMed
4. Kotsenas AL, Aase L, Arce M, Timimi FK, Dacy M, Young C, Wald JT. The Social Media DNA of Mayo Clinic-and Health Care. J Am Coll Radiol. 2018 Jan; 15 (1 Pt B):162-166 Epub 2017 Nov 08
   View PubMed
5. Kotsenas AL, Arce M, Aase L, Timimi FK, Young C, Wald JT. The Strategic Imperative for the Use of Social Media in Health Care. J Am Coll Radiol. 2018 Jan; 15 (1 Pt B):155-161 Epub 2017 Nov 09
   View PubMed
6. Guo YX, Lin ZM, Wang MJ, Dong YW, Niu HM, Young CY, Lou HX, Yuan HQ. Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro. Acta Pharmacol Sin. 2016 Jun; 37 (6):814-24 Epub 2016 May 02
   View PubMed
7. Hu Z, Zhang D, Wang D, Sun B, Safoor A, Young CY, Lou H, Yuan H. Bisbibenzyls, novel proteasome inhibitors, suppress androgen receptor transcriptional activity and expression accompanied by activation of autophagy in prostate cancer LNCaP cells. Pharm Biol. 2016; 54: (2)364-74.
   View PubMed
8. Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV. Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer. Onco Targets Ther. 2015; 8:1915-22 Epub 2015 July 30
   View PubMed
9. Zhang D, Cui Y, Niu L, Xu X, Tian K, Young CY, Lou H, Yuan H. Regulation of SOD2 and beta-arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells. Eur J Cell Biol. 2014 Jul; 93 (7):289-98 Epub 2014 June 02
   View PubMed
10. Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV. Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther. 2014 May; 13 (5):1067-77 Epub 2014 Mar 27
    View PubMed
11. Li Z, Guo Y, Jiang H, Zhang T, Jin C, Young CYF, Yuan H. Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 2014; 14(1):276.
    View PubMed
12. Yu C, Gong AY, Chen D, Solelo Leon D, Young CY, Chen XM. Phenethyl isothiocyanate inhibits androgen receptor-regulated transcriptional activity in prostate cancer cells through suppressing PCAF. Mol Nutr Food Res. 2013 Oct; 57(10):1825-33. Epub 2013 May 10.
    View PubMed
13. Liu YQ, Ji Y, Li XZ, Tian KL, Young CY, Lou HX, Yuan HQ. Retigeric acid B-induced mitophagy by oxidative stress attenuates cell death against prostate cancer cells in vitro. Acta Pharmacol Sin. 2013 Sep; 34(9):1183-91. Epub 2013 Jul 29.
    View PubMed
14. Liu Y, Gao F, Jiang H, Niu L, Bi Y, Young CY, Yuan H, Lou H. Induction of DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II inhibitor, promotes apoptosis in prostate cancer cells. Cancer Lett. 2013 Aug 28; 337(1):66-76. Epub 2013 May 18.
    View PubMed
15. Jiang H, Sun J, Xu Q, Liu Y, Wei J, Young CY, Yuan H, Lou H. Marchantin M: a novel inhibitor of proteasome induces autophagic cell death in prostate cancer cells. Cell Death Dis. 2013; 4:e761. Epub 2013 Aug 08.
    View PubMed
16. Hu Z, Kong F, Si M, Tian K, Yu LX, Young CY, Yuan H, Lou H. Riccardin D Exerts Its Antitumor Activity by Inducing DNA Damage in PC-3 Prostate Cancer Cells In Vitro and In Vivo. PLoS One. 2013; 8(9):e74387. Epub 2013 Sep 17.
    View PubMed
17. Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY, Chen XM. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate. 2012 Oct 1; 72(14):1514-22. Epub 2012 Feb 07.
    View PubMed
18. Hu Z, Gu Y, Han B, Zhang J, Li Z, Tian K, Young CY, Yuan H. Knockdown of AGR2 induces cellular senescence in prostate cancer cells. Carcinogenesis. 2012 Jun; 33(6):1178-86. Epub 2012 Mar 31.
    View PubMed
19. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, Donkena KV. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res. 2012 May 15; 18 (10):2882-95
    View PubMed
20. Gong AY, Eischeid AN, Xiao J, Zhao J, Chen D, Wang ZY, Young CY, Chen XM. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer. 2012; 12:492. Epub 2012 Oct 24.
    View PubMed
21. Liu YQ, Hu XY, Lu T, Cheng YN, Young CY, Yuan HQ, Lou HX. Retigeric acid B exhibits antitumor activity through suppression of nuclear factor-kappaB signaling in prostate cancer cells in vitro and in vivo. PLoS One. 2012; 7(5):e38000. Epub 2012 May 29.
    View PubMed
22. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019 Epub 2012 Feb 22
    View PubMed
23. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13 (3):365-77 Epub 2011 May 11
    View PubMed
24. Xi G, Hu X, Wu B, Jiang H, Young CY, Pang Y, Yuan H. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett. 2011 Aug 28; 307(2):141-8. Epub 2011 Apr 21.
    View PubMed
25. Zhang JS, Koenig A, Young C, Billadeau DD. GRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration. Mol Biol Cell. 2011 Jun 15; 22(12):2119-30. Epub 2011 Apr 20.
    View PubMed
26. Ding Y, Wang X, Xu A, Xu X, Tian K, Young CY, Yuan H. Associations of saposin C, Src, and androgen receptor upregulate the expression and function of androgen receptor in human prostate cancer cells. J Cell Biochem. 2011 Mar; 112(3):818-28.
    View PubMed
27. Wang XL, Kong F, Shen T, Young CY, Lou HX, Yuan HQ. Sesquiterpenoids from myrrh inhibit androgen receptor expression and function in human prostate cancer cells. Acta Pharmacol Sin. 2011 Mar; 32(3):338-44.
    View PubMed
28. Donkena KV, Young CY. Vitamin d, sunlight and prostate cancer risk. Adv Prev Med. 2011; 2011:281863 Epub 2011 June 08
    View PubMed
29. Liu H, Liu YQ, Liu YQ, Xu AH, Young CY, Yuan HQ, Lou HX. A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells. Chem Biol Interact. 2010 Dec 5; 188 (3):598-606 Epub 2010 Aug 06
    View PubMed
30. Donkena KV, Yuan H, Young CY. Vitamin Bs, one carbon metabolism and prostate cancer. Mini Rev Med Chem. 2010 Dec; 10 (14):1385-92
    View PubMed
31. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 2010 Jun 15; 42(6):363-9.
    View PubMed
32. Donkena KV, Yuan H, Young CY. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets. 2010 Jun; 10 (4):402-10
    View PubMed
33. Yuan H, Young CY, Tian Y, Liu Z, Zhang M, Lou H. Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem. 2010 Jun; 339(1-2):253-62. Epub 2010 Feb 11.
    View PubMed
34. Donkena KV, Karnes RJ, Young CY. Vitamins and prostate cancer risk. Molecules. 2010 Mar 12; 15 (3):1762-83
    View PubMed
35. Donkena KV, Young CY, Tindall DJ. Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int. 2010; 2010:302051 Epub 2010 June 29
    View PubMed
36. He M, Vanaja DK, Karnes RJ, Young CY. Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells. Prostate. 2009 Nov 1; 69 (15):1643-50
    View PubMed
37. Gong A, He M, Krishna Vanaja D, Yin P, Karnes RJ, Young CY. Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res. 2009 Jul; 53 (7):878-86
    View PubMed
38. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009 Jun; 27 (5):549-60
    View PubMed
39. He M, Young CY. New approaches to target the androgen receptor and STAT3 for prostate cancer treatments. Mini Rev Med Chem. 2009 Mar; 9 (3):395-400
    View PubMed
40. He M, Young CY. Mutant epidermal growth factor receptor vIII increases cell motility and clonogenecity in a prostate cell line RWPE1. J Endocrinol Invest. 2009 Mar; 32 (3):272-8
    View PubMed
41. Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A, Zhang JS, Ajtai K, Burghardt TP, Young CY. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest. 2009 Mar; 27 (3):264-72
    View PubMed
42. Yin P, Kawamura T, He M, Vanaja DK, Young CY. Phenethyl isothiocyanate induces cell cycle arrest and reduction of alpha- and beta-tubulin isotypes in human prostate cancer cells. Cell Biol Int. 2009 Jan; 33 (1):57-64 Epub 2008 Oct 11
    View PubMed
43. Zhang Y, Linn D, Liu Z, Melamed J, Tavora F, Young CY, Burger AM, Hamburger AW. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther. 2008 Oct; 7(10):3176-86.
    View PubMed
44. Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, Lou HX. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol. 2008 Jun 1; 75(11):2112-21. Epub 2008 Mar 15.
    View PubMed
45. Young CY, Yuan HQ, He ML, Zhang JY. Carotenoids and prostate cancer risk. Mini Rev Med Chem. 2008 May; 8 (5):529-37
    View PubMed
46. Gazi MH, He M, Cheville JC, Young CY. Downregulation of IgG Fc binding protein (Fc gammaBP) in prostate cancer. Cancer Biol Ther. 2008 Jan; 7 (1):70-5 Epub 2007 Oct 08
    View PubMed
47. Young CY. Recent approaches in chemoprevention of prostate cancer. Curr Cancer Drug Targets. 2007 Nov; 7 (7):681-8
    View PubMed
48. Ding Y, Yuan HQ, Kong F, Hu XY, Ren K, Cai J, Wang XL, Young CY. Ectopic expression of neurotrophic peptide derived from saposin C increases proliferation and upregulates androgen receptor expression and transcriptional activity in human prostate cancer cells. Asian J Androl. 2007 Sep; 9(5):601-9.
    View PubMed
49. Gazi MH, Gong A, Donkena KV, Young CY. Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun. Clin Chim Acta. 2007 May 1; 380 (1-2):145-50 Epub 2007 Feb 11
    View PubMed
50. Zhang HN, Yu CX, Zhang PJ, Chen WW, Jiang AL, Kong F, Deng JT, Zhang JY, Young CY. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol Sin. 2007 Mar; 28(3):423-30.
    View PubMed
51. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W, North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007 Feb; 69 (2):289-94
    View PubMed
52. Zhang JS, Gong A, Young CY. ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer. Oncogene. 2007 Jan 4; 26(1):111-22. Epub 2006 Jun 26.
    View PubMed
53. He ML, Yuan HQ, Jiang AL, Gong AY, Chen WW, Zhang PJ, Young CY, Zhang JY. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells. Cancer. 2006 Jun 15; 106(12):2547-55.
    View PubMed
54. Chung BH, Lee HY, Lee JS, Young CY. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett. 2006 May 18; 236(2):222-8. Epub 2005 Jul 18.
    View PubMed
55. Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res. 2006 Feb 15; 12 (4):1128-36
    View PubMed
56. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer. 2005 Jul; 43 (3):249-59
    View PubMed
57. Yuan H, Gong A, Young CY. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis. 2005 Apr; 26 (4):793-801 Epub 2005 Jan 20
    View PubMed
58. Zhang PJ, Zhang JY, Young CYF, Kao PC, Chen WW, Jiang AL, Zhang LY, Guo Q. Decoy androgen-responsive element DNA can inhibit androgen receptor transactivation of the PSA promoter gene. Ann Clin Lab Sci. 2005 Sum; 35(3):278-84.
    View PubMed
59. Yuan H, Pan Y, Young CY. Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett. 2004 Sep 30; 213 (2):155-63
    View PubMed
60. Grossmann ME, Madden BJ, Gao F, Pang YP, Carpenter JE, McCormick D, Young CY. Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Exp Cell Res. 2004 Jul 01; 297: (1)108-17.
    View PubMed
61. Young CYF. The role of nonsteroidal antinflammatory drugs in cancer chemoprevention. Drugs Future. 2004 May; 29(5):467-78.
    View PubMed
62. Cho SD, Jiang C, Malewicz B, Dong Y, Young CYF, Kang KS, Lee YS, Ip C, Lu JX. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Molecular Cancer Therapeutics. 2004 May; 3(5):605-11.
    View PubMed
63. Young CY, Jatoi A, Ward JF, Blute ML. The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Curr Med Chem. 2004 Apr; 11 (7):909-23
    View PubMed
64. Wang MH, Grossmann ME, Young CY. Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. Br J Cancer. 2004 Feb 23; 90 (4):926-31
    View PubMed
65. Jatoi A, Ellison N, Burch PA, Quesenberry J, Shogren K, Sloan JA, Young CYF. Prostate cancer patients with maspin-negative tumors can live over a decade. Cancer Therapy. 2004; 2:173-6.
    
66. Spitzweg C, Scholz IV, Bergert ER, Tindall DJ, Young CYF, Goke B, Morris JC. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology. 2003 Aug; 144(8):3423-32.
    View PubMed
67. Pan Y, Zhang JS, Gazi MH, Young CY. The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2003 Aug; 12(8):769-74.
    View PubMed
68. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003 Jul 15; 63 (14):3877-82
    View PubMed
69. Wang MH, Abreu-Delgado Y, Young CY. Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4. Urology. 2003 Jul; 62 (1):167-71
    View PubMed
70. Chen WW, Zhang JY, Young CYF, Zhang LY, Chen LC, Zhao J. The RFA regulatory sequence-binding protein in the promoter of prostate-specific antigen gene. Sci China C Life Sci. 2003 Apr; 46(2):184-93.
    
71. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003 Mar 15; 97 (6):1442-6
    View PubMed
72. Liu J, Zhang JS, Young CYF, Kao PC. Polymorphisms of prostate-specific antigen gene promoter: Determination from cord blood collected on filter paper. Ann Clin Lab Sci. 2003 Fal; 33(4):429-34.
    View PubMed
73. Meng FJ, Shan AL, Jin L, Young CYF. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev. 2002 Mar; 11(3):305-9.
    View PubMed
74. Vanaja DK, Mitchell SH, Vanaja DK, Toft DO, Young CY. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones. 2002 Jan; 7 (1):55-64
    View PubMed
75. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001 Oct; 8 (20):1524-31
    View PubMed
76. Zhu W, Zhang JS, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis. 2001 Sep; 22 (9):1399-403
    View PubMed
77. Chung BH, Mitchell SH, Zhang JS, Zhang JS, Young CY. Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis. 2001 Aug; 22 (8):1201-6
    View PubMed
78. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate. 2001 Jun 15; 48 (1):7-15
    View PubMed
79. Xie X, Zhao X, Liu Y, Young CY, Tindall DJ, Slawin KM, Spencer DM. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther. 2001 Mar 20; 12(5):549-61.
    View PubMed
80. Xing N, Chen Y, Mitchell SH, Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar; 22 (3):409-14
    View PubMed
81. Zhu W, Young CY. Androgen-Dependent transcriptional regulation of the prostate-specific antigen gene by thyroid hormone 3,5,3'-L-triiodothyronine. J Androl. 2001 Jan-Feb; 22(1):136-41.
    View PubMed
82. Donkena KV, Young CYF. Recent progress in prevention and other perspectives of prostate cancer. Recent Research Development in Cancer. 2001; 3:127-48.
    
83. Slawin KM, Shariat SF, Nguyen C, Leventis AK, Song W, Kattan MW, Young CY, Tindall DJ, Wheeler TM. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Cancer Res. 2000 Dec 15; 60(24):7142-8.
    View PubMed
84. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000 Nov 15; 60 (22):6526-30
    View PubMed
85. Mitchell SH, Murtha PE, Zhang S, Zhu W, Young CY. An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol. 2000 Oct 25; 168 (1-2):89-99
    View PubMed
86. Vanaja DK, Grossmann ME, Celis E, Young CY. Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Res. 2000 Sep 1; 60(17):4714-8.
    View PubMed
87. Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene. 2000 Apr 6; 19(15):1924-32.
    View PubMed
88. Butler R, Mitchell SH, Tindall DJ, Young CY. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ. 2000 Jan; 11 (1):49-61
    View PubMed
89. Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJ, Tindall DJ, Young CY, Sauter ER, Diamandis EP. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br J Cancer. 2000 Jan; 82(2):361-7.
    View PubMed
90. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999 Dec 1; 59 (23):5892-5
    View PubMed
91. Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology. 1999 Nov; 54(5):839-45.
    View PubMed
92. Zhu W, Smith A, Young CY. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology. 1999 Nov; 140 (11):5451-4
    View PubMed
93. Klee GG, Goodmanson MK, Jacobsen SJ, Young CY, Finlay JA, Rittenhouse HG, Wolfert RL, Tindall DJ. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem. 1999 Jun; 45 (6 Pt 1):800-6
    View PubMed
94. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999 May 1; 59 (9):2136-41
    View PubMed
95. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Roche P, Wolfert RL, Saeid MS, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology. 1999 May; 53 (5):939-44
    View PubMed
96. Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ, Young CY. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology. 1999 Apr; 140(4):1665-71.
    View PubMed
97. Charlesworth MC, Young CY, Miller VM, Tindall DJ. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl. 1999 Mar-Apr; 20(2):220-9.
    View PubMed
98. Young CYF, Butler R. Green tea. Minnesota Physician. 1999; XIII(2):30-1.
    
99. Zhang S, Hsieh M, Zhu W, Klee G, Tindall D, Young C. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology. 1999; 140(4):1665-71.
    
100. Paschka AG, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett. 1998 Aug 14; 130 (1-2):1-7
     View PubMed
101. Murtha PE, Zhu W, Zhang J, Zhang S, Young CY. Effects of Ca++ mobilization on expression of androgen-regulated genes: interference with androgen receptor-mediated transactivation by AP-I proteins. Prostate. 1997 Dec 1; 33 (4):264-70
     View PubMed
102. Zhang J, Zhang S, Murtha PE, Zhu W, Hou SS, Young CY. Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation. Nucleic Acids Res. 1997 Aug 1; 25 (15):3143-50
     View PubMed
103. Corey E, Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CY, Ellis WJ, Vessella RL. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology. 1997 Aug; 50(2):184-8.
     View PubMed
104. Hsieh ML, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, Tindall DJ, Young CY. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res. 1997 Jul 1; 57(13):2651-6.
     View PubMed
105. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Roche P, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology. 1997 Jun; 49 (6):857-62
     View PubMed
106. Charlesworth MC, Young CY, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA, Tindall DJ. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology. 1997 Mar; 49 (3):487-93
     View PubMed
107. Zhang S, Murtha PE, Young CY. Defining a functional androgen responsive element in the 5' far upstream flanking region of the prostate-specific antigen gene. Biochem Biophys Res Commun. 1997 Feb 24; 231(3):784-8.
     View PubMed
108. Rittenhouse HG, Tindall DJ, Klee GG, Young CYF, Bostwick D, Saedi MM, Grauer L, Mikolajczyk S, Finlay J, Kuus-Reichel K, et al. Characterization and evaluation of hK2: a potential prostate cancer marker, closely related to PSA. Proceedings of the First International Consultation on Prostate Cancer. 1997; 1:133-41.
     
109. Mohr DN, Carpenter PC, Claus PC, Fisk T, Goodnature DJ, Hagen P, Halloran MJ, Higgins MC, Suermondt HJ, VanScoy R, Young CY. The development of a modular, component-based, electronic medical record system. HIMSS '97. The big picture: proceedings of the. 1997 Annual HIMSS Conference. 1997; 1:33-43.
     
110. Grauer LS, Charlesworth MC, Saedi MS, Finlay JA, Liu RS, Kuus-Reichel K, Young CY, Tindall DJ. Identification of human glandular kallikrein hK2 from LNCaP cells. J Androl. 1996 Jul-Aug; 17(4):353-9.
     View PubMed
111. Young CY, Seay T, Hogen K, Charlesworth MC, Roche PC, Klee GG, Tindall DJ. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Prostate Suppl. 1996; 7:17-24.
     View PubMed
112. Young CYF, Murtha PE, Andrews PE, Lindzey JK, Tindall DJ. Antagonism of androgen action in prostate tumor cells by retinoic acid. Year Book of Geriatrics and Gerontology, Mosby-Year Book, Inc., Chicago, IL. 1996.
     
113. Zhu W, Murtha PE, Young CY. Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. Biochem Biophys Res Commun. 1995 Sep 25; 214(3):1130-7.
     View PubMed
114. Saedi MS, Cass MM, Goel AS, Grauer L, Hogen KL, Okaneya T, Griffin BY, Klee GG, Young CY, Tindall DJ. Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies. Molecular & Cellular Endocrinology. 1995 Apr 1; 109(2):237-41.
     View PubMed
115. Schaffner DL, Barrios R, Shaker MR, Rajagopalan S, Huang SL, Tindall DJ, Young CY, Overbeek PA, Lebovitz RM, Lieberman MW. Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and gastrointestinal tract neoplasms. Lab Invest. 1995 Mar; 72(3):283-90.
     View PubMed
116. Young CY, Andrews PE, Tindall DJ. Expression and androgenic regulation of human prostate-specific kallikreins. J Androl. 1995 Mar-Apr; 16(2):97-9.
     View PubMed
117. Young CYF, Andrews PE, Tindall DJ. Expression and regulation of human prostate-specific kallikreins. J Andrology. 1995; 16:97-9.
     
118. Young CY, Murtha PE, Andrews PE, Lindzey JK, Tindall DJ. Antagonism of androgen action in prostate tumor cells by retinoic acid. Prostate. 1994 Jul; 25 (1):39-45
     View PubMed
119. Mak P, Young CY, Tindall DJ. A novel yeast expression system to study androgen action. Recent Prog Horm Res. 1994; 49:347-52.
     View PubMed
120. Lindzey J, Kumar MV, Grossman M, Young C, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam Horm. 1994; 49:383-432
     View PubMed
121. Young CY, Murtha PE, Zhang J. Tumor-promoting phorbol ester-induced cell death and gene expression in a human prostate adenocarcinoma cell line. Oncol Res. 1994; 6(4-5):203-10.
     View PubMed
122. Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. Biochemistry. 1993 Jun 29; 32 (25):6459-64
     View PubMed
123. Andrews PE, Young CY, Montgomery BT, Tindall DJ. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res. 1992 Mar 15; 52(6):1525-9.
     View PubMed
124. Young CY, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 1992 Jan 28; 31 (3):818-24
     View PubMed
125. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate. 1992; 21 (1):63-73
     View PubMed
126. Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. 1991 Jul 15; 51(14):3748-52.
     View PubMed
127. Young CY, Qiu SD, Prescott JL, Tindall DJ. Overexpression of a partial human androgen receptor in E. coli: characterization of steroid binding, DNA binding, and immunological properties. Mol Endocrinol. 1990 Dec; 4(12):1841-9.
     View PubMed
128. Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol. 1990 Dec; 144 (6):1550-6
     View PubMed
129. He WW, Fischer LM, Sun S, Bilhartz DL, Zhu XP, Young CY, Kelley DB, Tindall DJ. Molecular cloning of androgen receptors from divergent species with a polymerase chain reaction technique: complete cDNA sequence of the mouse androgen receptor and isolation of androgen receptor cDNA probes from dog, guinea pig and clawed frog. Biochem Biophys Res Commun. 1990 Sep 14; 171 (2):697-704
     View PubMed
130. Shao TC, Kong A, Young C, Chu WH, Tindall DJ, Cunningham GR. Prostatein C3-mRNA: a sensitive marker of androgen-responsiveness in prostate explant cultures. Prostate. 1990; 17(1):41-55.
     View PubMed
131. Young CY, Johnson MP, Prescott JL, Tindall DJ. The androgen receptor of the testicular-feminized (Tfm) mutant mouse is smaller than the wild-type receptor. Endocrinology. 1989 Feb; 124(2):771-5.
     View PubMed
132. Young CY, Murthy LR, Prescott JL, Johnson MP, Rowley DR, Cunningham GR, Killian CS, Scardino PT, VonEschenbach A, Tindall DJ. Monoclonal antibodies against the androgen receptor: recognition of human and other mammalian androgen receptors. Endocrinology. 1988 Jul; 123(1):601-10.
     View PubMed
133. Johnson MP, Young CY, Rowley DR, Tindall DJ. A common molecular weight of the androgen receptor monomer in different target tissues. Biochemistry. 1987 Jun 2; 26(11):3174-82.
     View PubMed
134. Rowley DR, Premont RT, Johnson MP, Young CY, Tindall DJ. Properties of an intermediate-sized androgen receptor: association with RNA. Biochemistry. 1986 Nov 4; 25(22):6988-95.
     View PubMed
135. Murthy LR, Johnson MP, Rowley DR, Young CY, Scardino PT, Tindall DJ. Characterization of steroid receptors in human prostate using mibolerone. Prostate. 1986; 8(3):241-53.
     View PubMed
136. Young CYF, Chen CP, Tai FH. Meningococcus group carries status in Chinese recruits. Chinese Journal of Microbiology. 1977; 10:6-9.
     
137. Young CYF, Yang SC, Tai FH. Reovirus antibodies among animals in Taiwan. Chinese Journal of Microbiology. 1976; 9:1-4.
     View PubMed